DE69836830D1 - USE OF PROTEINS FROM THE MIDKINE FAMILY IN THE TREATMENT OF ISCHEMIC ILLNESSES - Google Patents

USE OF PROTEINS FROM THE MIDKINE FAMILY IN THE TREATMENT OF ISCHEMIC ILLNESSES

Info

Publication number
DE69836830D1
DE69836830D1 DE69836830T DE69836830T DE69836830D1 DE 69836830 D1 DE69836830 D1 DE 69836830D1 DE 69836830 T DE69836830 T DE 69836830T DE 69836830 T DE69836830 T DE 69836830T DE 69836830 D1 DE69836830 D1 DE 69836830D1
Authority
DE
Germany
Prior art keywords
ischemic
disorders
treating
disease
cerebral
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69836830T
Other languages
German (de)
Other versions
DE69836830T2 (en
Inventor
Yoshihiro Yoshida
Shinya Ikematsu
Sadatoshi Sakuma
Munehiro Oda
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Anagenics Ltd
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of DE69836830D1 publication Critical patent/DE69836830D1/en
Application granted granted Critical
Publication of DE69836830T2 publication Critical patent/DE69836830T2/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Neurology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Psychology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

A pharmaceutical composition for treating or preventing cytopathy caused by ischemia, comprising a midkine family protein as an active ingredient, and a pharmaceutical composition for treating or preventing ischemic disorders, comprising a midkine family protein as an active ingredient, are provided. Midkine is efficacious in treating or preventing ischemic disorders and cytopathy caused by ischemia and can remarkably prevent, for example, the development of cerebral infarction, a representative of ischemic brain disorders. The pharmaceutical composition of the present invention is also efficacious against, for example, cerebral ischemic disorders such as cerebrovascular spasm following a subarachnoid hemorrhage, Alzheimer's disease, senile dementia of Alzheimer's type, and cerebrovascular senile dementia, as well as cerebral ischemia, transient cerebral ischemic disease, and head trauma, and other cerebrovascular diseases such as Parkinson's disease, Huntington's chorea, and amyotrophic regressive disorders.
DE69836830T 1997-09-26 1998-09-25 USE OF PROTEINS FROM THE MIDKINE FAMILY IN THE TREATMENT OF ISCHEMIC ILLNESSES Expired - Lifetime DE69836830T2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP27943597 1997-09-26
JP27943597 1997-09-26
PCT/JP1998/004299 WO1999016463A1 (en) 1997-09-26 1998-09-25 Preventives or remedies for ischemic diseases

Publications (2)

Publication Number Publication Date
DE69836830D1 true DE69836830D1 (en) 2007-02-15
DE69836830T2 DE69836830T2 (en) 2007-10-11

Family

ID=17611037

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69836830T Expired - Lifetime DE69836830T2 (en) 1997-09-26 1998-09-25 USE OF PROTEINS FROM THE MIDKINE FAMILY IN THE TREATMENT OF ISCHEMIC ILLNESSES

Country Status (9)

Country Link
EP (1) EP1057489B1 (en)
JP (1) JP5400006B2 (en)
KR (1) KR100554294B1 (en)
CN (1) CN1278184A (en)
AT (1) ATE350051T1 (en)
AU (1) AU9185198A (en)
CA (1) CA2304956C (en)
DE (1) DE69836830T2 (en)
WO (1) WO1999016463A1 (en)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MXPA00010110A (en) * 1998-04-17 2002-08-06 Angiogenix Inc Therapeutic angiogenic factors and methods for their use.
WO2000002578A1 (en) * 1998-07-10 2000-01-20 Meiji Milk Products Co., Ltd. Remedies for apoptosis-associated diseases
CA2341638C (en) 1998-08-24 2010-05-11 Meiji Milk Products Co., Ltd. Use of a midkine inhibitor
JP4791770B2 (en) * 2004-12-06 2011-10-12 株式会社セルシグナルズ Composition for treating or preventing myocardial injury or heart failure
US8288343B2 (en) 2007-03-30 2012-10-16 National University Corporation Nagoya University Activation of endothelial nitric oxide synthase by midkine and uses therefor in effecting vasodilation
CN103432681A (en) * 2007-05-25 2013-12-11 上海泽生科技开发有限公司 Medicine preparation and device comprising NRG (neuregulin)
WO2014202833A1 (en) * 2013-06-18 2014-12-24 University Of Helsinki Treatment of neuronal injuries
WO2019133535A1 (en) * 2017-12-27 2019-07-04 Gen Suzuki Cardiosphere-derived cell sheet and methods of making and using the same

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0827021A (en) * 1994-07-22 1996-01-30 Mitsui Toatsu Chem Inc Medicinal composition
JP3553655B2 (en) * 1994-09-02 2004-08-11 喬 村松 Method for producing polypeptide
US5629284A (en) * 1995-07-24 1997-05-13 Meiji Milk Products Co., Ltd. Method for treating retinal diseases
CN1177611C (en) * 1997-03-12 2004-12-01 村松乔 Preventive and therapeutic compsns. for drug induced nephropathy and hepatitis

Also Published As

Publication number Publication date
KR20010030716A (en) 2001-04-16
EP1057489A1 (en) 2000-12-06
WO1999016463A1 (en) 1999-04-08
EP1057489A4 (en) 2004-10-27
JP2010270156A (en) 2010-12-02
AU9185198A (en) 1999-04-23
EP1057489B1 (en) 2007-01-03
CN1278184A (en) 2000-12-27
CA2304956A1 (en) 1999-04-08
DE69836830T2 (en) 2007-10-11
KR100554294B1 (en) 2006-02-24
CA2304956C (en) 2013-12-03
JP5400006B2 (en) 2014-01-29
ATE350051T1 (en) 2007-01-15

Similar Documents

Publication Publication Date Title
FI973446A (en) Benzylpiperidines and piperazines as muscarinic antagonists
DE69429527T2 (en) INHIBITORS OF BETA AMYLOID PROTEIN PRODUCTION
DK0457295T3 (en) Use of a protein phosphorylation modulator in the treatment of amyloidosis associated with Alzheimer's disease
DE69332462D1 (en) Protease and related DNS connections
HK1063012A1 (en) Napthoquinone derivatives as inhibitors of tau aggregation for the treatment of alzheimer's and related neurodegenerative disorders
CA2319308A1 (en) Pharmaceutical agents
FI961809A0 (en) Novel (R) -5-carbamoyl-8-fluoro-3-N, N-disubstituted amino 3,4-dihydro-2H-1-benzopyrans
ATE425750T1 (en) USE OF MEDIUM CHAIN TRIGLYCERIDES FOR THE TREATMENT AND PREVENTION OF ALZHEIMER'S DISEASE
ATE275415T1 (en) COMPOSITION CONTAINING A MYELIN-ASSOCIATED GLYCOPROTEIN (MAG) INHIBITOR WHICH CONTAINS AN ALTERED OR MUTATED FORM OF MAG
DE69836830D1 (en) USE OF PROTEINS FROM THE MIDKINE FAMILY IN THE TREATMENT OF ISCHEMIC ILLNESSES
DE69433309D1 (en) Preventive or therapeutic agents for Alzheimer's disease, a seven-test method, and human tau protein kinase
ATE526981T1 (en) USE OF VEGF 165 AND HOMOLOGUES TO TREAT NEUROLOGICAL DISORDERS
DE60131550D1 (en) Gsk3-polypeptide
DE69805305D1 (en) USE OF PHANQUINON FOR THE TREATMENT OF ALZHEIMER'S DISEASE
NO903384D0 (en) PROCEDURE FOR THE PREPARATION OF 4- (N-SUBSTITUTED AMINO) -2-BUTYNYL-1-URINES AND TIOUR INGREDIENTS AND DERIVATIVES THEREOF.
ATE116851T1 (en) 5-ARYL-3H-1,2,4-TRIAZOLE-3-ONE AND ITS USE IN THE TREATMENT OF NEURODEGENERATIVE CONDITIONS.
WO1998020034A3 (en) Novel serine protease inhibitor nucleic acid molecules, proteins and uses thereof
DE69028603D1 (en) MEDICINES FOR BETTER BRAIN EFFECT
NO953072L (en) Use of inhibitors of ornithine aminotransferase for the manufacture of a medicament for the treatment of Alzheimer's disease
ES2132308T3 (en) 4- (2-CHLORINE-3-CYAN-PHENYL) -1,4-DIHYDRO-2,6-DIMETIL-PIRIDINA-3,5-DICARBOXILATO DE ISOPROPILO AND 2-METOXIETILO.
DE69503635T2 (en) PYRROLIDE DERIVATIVES FOR TREATING CCK AND GASTRIN-DEPENDENT DISEASES
EP0402733A3 (en) Agent for the treatment of central nervous system illnesses and for the enhancement of cerebral blood flow

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8327 Change in the person/name/address of the patent owner

Owner name: MEDICAL THERAPIES LTD., SYDNEY, NEW SOUTH WALE, AU